Antibody therapy in pancreatic cancer: mAb-ye we're onto something?

Anna J. Boland, Anthony A. O'Kane, Richard Buick, Daniel B Longley, Christopher J Scott

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Pancreatic cancer remains an extremely deadly disease, with little improvement seen in treatment or outcomes over the last 40 years. Targeted monoclonal antibody therapy is one area that has been explored in attempts to tackle this disease. This review examines antibodies that have undergone clinical evaluation in pancreatic cancer. These antibodies target a wide variety of molecules, including tumour cell surface, stromal, immune and embryonic pathway targets. We discuss the therapeutic utility of these therapies both as monotherapeutics and in combination with other treatments such as chemotherapy. While antibody therapy for pancreatic cancer has yet to yield significant success, lessons learned from research thus far highlights future directions that may help overcome observed hurdles to yield clinically efficacious results.
Original languageEnglish
Article number188557
Number of pages20
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number1
Early online date01 May 2021
Publication statusPublished - Aug 2021


  • Monoclonal antibody
  • Oncology
  • Pancreatic cancer
  • Targeted therapy


Dive into the research topics of 'Antibody therapy in pancreatic cancer: mAb-ye we're onto something?'. Together they form a unique fingerprint.

Cite this